Bio-Techne (TECH) 10-K/A 9 Oct 19 2019 FY Annual report (amended) Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Billions	12 Months Ended
	Jun. 30, 2019	Aug. 26, 2019	Dec. 31, 2018
Document Information [Line Items]
Entity Registrant Name	BIO-TECHNE Corp
Entity Central Index Key	0000842023
Trading Symbol	tech
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		38,063,504
Entity Public Float			$ 5.5
Entity Shell Company	false
Document Type	10-K/A
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) amends Bio-Techne Corporation’s (the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2019, as filed with the Securities and Exchange Commission (“SEC”) on August 28, 2019 (the “Original Filing”), solely to provide a revised version of KPMG LLP’s (“KPMG”) report, which corrects certain clerical items and a statement in the previously filed version that KPMG did not express an opinion on the Company’s internal controls over financial reporting, and makes a clerical correction in Item 9A to conform the name of the entity the Company acquired on June 4, 2019 to the Company’s consolidated financial statements. These changes to the filed version of KPMG's report included in the original filing do not affect KPMG's unqualified opinion on the Company's consolidated financial statements or KPMG's unqualified opinion on internal control over financial reporting included in the Original Filing and this Amendment No. 1. As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 includes a new consent of KPMG (Exhibit 23.1), new certifications from the Company's principal executive officer (Exhibit 31.1) and principal financial officer (Exhibit 31.2) and new Section 1350 certifications (Exhibit 32.1 and 32.2) dated as of the date of filing of this Amendment No. 1. This Amendment No. 1 consists solely of the preceding cover page, this explanatory note, Part II., Item 8., “Consolidated Financial Statements and Supplementary Data,” in its entirety, Part IV., Item 15., “Exhibits and Financial Statement Schedules,” in its entirety, the signature page, and the new certifications from the Company’s principal executive officer and principal financial officer. Except as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information in any other item of the Original Filing. Amendment No. 1 speaks as of the date of the Original Filing, does not reflect events that may have occurred after the date of the Original Filing and does not modify or update in any way the disclosures made in the Original Filing, except as described above. Amendment No. 1 should be read in conjunction with the Original Filing and with the Company’s subsequent filings with the SEC.
Title of 12(b) Security	Common Stock

Consolidated Statements of Earn

Consolidated Statements of Earnings and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Net sales	$ 714,006	$ 642,993	$ 563,003
Cost of sales	240,515	210,850	188,462
Gross margin	473,491	432,143	374,541
Operating expenses:
Selling, general and administrative	264,359	240,636	200,443
Research and development	62,413	55,329	53,514
Total operating expenses	326,772	295,965	253,957
Operating income	146,719	136,178	120,584
Other income (expense):
Interest expense	(21,705)	(10,188)	(7,361)
Interest income	569	409	304
Other non-operating income (expense), net	(13,568)	(447)	(1,566)
Total other income (expense), net	(34,704)	(10,226)	(8,623)
Income before income taxes	112,015	125,952	111,961
Income taxes (benefit)	15,942	(198)	35,875
Net earnings	96,072	126,150	76,086
Other comprehensive income (loss):
Foreign currency translation adjustments	(4,487)	(1,572)	(3,061)
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax of $2,921 in FY19	(9,537)
Unrealized gains (losses) on available-for-sale investments, net of tax of $398 in FY18 and $(6,501) in FY17		5,693	24,531
Other comprehensive income (loss)	(14,024)	4,121	21,470
Comprehensive income	$ 82,048	$ 130,271	$ 97,556
Earnings per share:
Basic (in dollars per share)	$ 2.54	$ 3.36	$ 2.04
Diluted (in dollars per share)	$ 2.47	$ 3.31	$ 2.03
Weighted average common shares outstanding:
Basic (in shares)	37,781	37,476	37,313
Diluted (in shares)	38,892	38,055	37,500

Consolidated Statements of Ea_2

Consolidated Statements of Earnings and Comprehensive Income (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Unrealized gains (losses) on derivative instruments, tax	$ 2,921
Unrealized gains (losses) on available-for-sale investments, tax		$ 398	$ (6,501)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 100,886	$ 121,990
Short-term available-for-sale investments	65,147	59,764
Accounts receivable, less allowance for doubtful accounts of $980 and $839, respectively	137,466	120,296
Inventories	91,050	85,648
Other current assets	18,058	10,668
Total current assets	412,607	398,366
Property and equipment, net	154,039	145,348
Goodwill	732,667	597,890
Intangible assets, net	579,429	446,332
Other assets	5,668	5,266
Total assets	1,884,410	1,593,202
Current liabilities:
Trade accounts payable	16,210	18,452
Salaries, wages and related accruals	28,638	23,710
Accrued expenses	26,389	20,361
Contract liabilities	9,084	8,109
Income taxes payable	5,764	8,878
Contingent consideration payable	3,400
Current portion of long-term debt obligations	12,500
Total current liabilities	101,985	79,510
Deferred income taxes	89,754	86,293
Long-term debt obligations	492,660	339,000
Long-term contingent consideration payable	9,200
Other long-term liabilities	25,222	9,338
Shareholders' equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding
Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 37,934,040 and 37,607,500 shares, respectively	379	376
Additional paid-in capital	316,797	246,568
Retained earnings	931,934	876,931
Accumulated other comprehensive loss	(83,521)	(44,814)
Total shareholders' equity	1,165,589	1,079,061
Total liabilities and shareholders’ equity	$ 1,884,410	$ 1,593,202

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Accounts receivable, allowance for doubtful accounts	$ 980	$ 839
Undesignated capital stock, no par (in dollars per share)	$ 0	$ 0
Undesignated capital stock, shares authorized (in shares)	5,000,000	5,000,000
Undesignated capital stock, shares issued (in shares)	0	0
Undesignated capital stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	37,934,040	37,607,500
Common stock, shares outstanding (in shares)	37,934,040	37,607,500

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Jun. 30, 2016	37,254,000
Balance at Jun. 30, 2016	$ 372	$ 178,760	$ 770,553	$ (70,405)	$ 879,280
Net earnings			76,086		76,086
Other comprehensive income (loss)				21,470	21,470
Surrender and retirement of stock to exercise options (in shares)	(3,000)
Surrender and retirement of stock to exercise options		(275)			$ (275)
Common stock issued for exercise of options (in shares)	63,000				63,000
Common stock issued for exercise of options	$ 2	4,509			$ 4,511
Common stock issued for restricted stock awards (in shares)	31,000
Common stock issued for restricted stock awards			(287)		(287)
Cash dividends			(47,325)		(47,325)
Stock-based compensation expense		14,418			14,418
Tax benefit from exercise of stock options		514			514
Common stock issued to employee stock purchase plan (in shares)	11,000
Common stock issued to employee stock purchase plan		1,022			1,022
Employee stock purchase plan expense		213			213
Balances (in shares) at Jun. 30, 2017	37,356,000
Balance at Jun. 30, 2017	$ 374	199,161	799,027	(48,935)	949,627
Net earnings			126,150		126,150
Other comprehensive income (loss)				4,121	$ 4,121
Common stock issued for exercise of options (in shares)	204,000				204,000
Common stock issued for exercise of options	$ 2	17,661			$ 17,663
Common stock issued for restricted stock awards (in shares)	34,000
Common stock issued for restricted stock awards			(273)		(273)
Cash dividends			(47,973)		(47,973)
Stock-based compensation expense		27,959			27,959
Common stock issued to employee stock purchase plan (in shares)	14,000
Common stock issued to employee stock purchase plan		1,506			1,506
Employee stock purchase plan expense		281			$ 281
Balances (in shares) at Jun. 30, 2018	37,608,000				37,607,500
Balance at Jun. 30, 2018	$ 376	246,568	876,931	(44,814)	$ 1,079,061
Net earnings			96,072		96,072
Other comprehensive income (loss)				(14,024)	$ (14,024)
Common stock issued for exercise of options (in shares)	382,000				383,000
Common stock issued for exercise of options	$ 4	36,272			$ 36,276
Common stock issued for restricted stock awards (in shares)	29,000
Common stock issued for restricted stock awards			(2,575)		(2,575)
Cash dividends			(48,366)		(48,364)
Stock-based compensation expense		31,775			31,775
Common stock issued to employee stock purchase plan (in shares)	10,000
Common stock issued to employee stock purchase plan		1,676			1,676
Employee stock purchase plan expense		505			505
Cumulative effect adjustments due to adoption of new accounting standards and other at Jun. 30, 2018			25,276	(24,682)	$ 594
Share repurchases (in shares)	(95,000)				(95,000)
Share repurchases	$ (1)		(15,404)		$ (15,405)
Balances (in shares) at Jun. 30, 2019	37,934,000				37,934,040
Balance at Jun. 30, 2019	$ 379	$ 316,797	$ 931,934	$ (83,521)	$ 1,165,589

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net earnings	$ 96,072	$ 126,150	$ 76,086
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	78,171	64,463	60,036
Costs recognized on sale of acquired inventory	3,739	2,455	3,037
Deferred income taxes	(13,582)	(46,716)	(3,433)
Stock-based compensation expense	32,280	28,240	14,631
Fair value adjustment to contingent consideration payable	(2,000)	20,100	18,400
Contingent consideration payments		(26,600)	(11,800)
Gain on investment, net	(3,702)	(397)
Fair value adjustment on available for sale investments	16,067
Other operating activity	2,325	776	2,215
Change in operating assets and liabilities, net of acquisitions:
Trade accounts and other receivables	(15,000)	(2,700)	(19,686)
Inventories	(13,647)	(13,327)	(732)
Prepaid expenses	(698)	2,782	(2,088)
Trade accounts payable and accrued expenses	6,101	5,026	5,695
Salaries, wages and related accruals	5,013	(89)	661
Income taxes payable	(9,520)	10,204	699
Net cash provided by operating activities	181,619	170,367	143,721
Cash flows from investing activities:
Proceeds from sale and maturities of available-for-sale investments	21,579	36,390	6,079
Purchase of available-for-sale investments	(43,475)	(8,571)	(3,069)
Additions to property and equipment	(25,411)	(20,934)	(15,179)
Acquisitions, net of cash acquired	(289,492)	(67,851)	(253,785)
Investment in unconsolidated entity		21,574	(40,000)
Other investing activities		680
Net cash used in investing activities	(336,799)	(38,712)	(305,954)
Cash flows from financing activities:
Cash dividends	(48,364)	(47,973)	(47,325)
Proceeds from stock option exercises	37,950	19,170	5,257
Re-purchases of common stock	(15,405)
Excess tax benefit from stock option exercises			514
Borrowings under line-of-credit agreement	580,000	55,000	368,500
Payments on line-of-credit	(413,500)	(59,500)	(116,500)
Contingent consideration payments		(61,900)	(20,316)
Other financing activities	(6,297)	(3,985)	(1,017)
Net cash provided by (used in) financing activities	134,384	(99,188)	189,113
Effect of exchange rate changes on cash and cash equivalents	(308)	(2,089)	495
Net change in cash and cash equivalents	(21,104)	30,378	27,375
Cash and cash equivalents at beginning of year	121,990	91,612	64,237
Cash and cash equivalents at end of year	$ 100,886	$ 121,990	$ 91,612

Note 1 - Description of Busines

Note 1 - Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. Description of Business and Summary of Significant Accounting Policies: Description of business: Use of estimates: Principles of consolidation: Translation of foreign financial statements: Revenue recognition: ASC 606 Revenue from Contracts with Customers July 1, 2018 606 606 Recently Adopted Accounting Pronouncements 1 606 2 ASC 606 Research and development: Advertising costs: $4.1 $3.8 $4.5 2019, 2018, 2017 Income taxes: not fifty See Note 11 Comprehensive income: not Cash and cash equivalents: three Available-for-sale investments: three six 2019 2018 02 July 1, 2018, Recently Adopted Accounting Pronouncements 1. 2018 2017. Trade accounts receivable: not Inventories: first first not For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no ASC 330 Property and equipment: 3 5 5 40 Contingent Consideration: may Intangibles assets: 1 20 no Impairment of long-lived assets and amortizable intangibles: may not not 1 2 3 not The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may No no 2017, 2018, 2019. Impairment of goodwill: fourth not 1 2 3 4 To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one 2019 Goodwill Impairment Analyses At the beginning of the quarter ended March 31, 2019, Because our quantitative analysis performed as of January 1, 2019 not The quantitative assessments completed as of January 1, 2019 The Company has elected April 1 June 30. April 1. not In conducting our annual goodwill impairment test, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not Based on its annual analysis, the Company determined there was no no June 30, 2019 2018 2017 Goodwill Impairment Analyses In completing our 2018 2017 2017 04, The quantitative assessment completed as of June 30, 2018 2017 There has been no 350 July 1, 2002. Investments in unconsolidated entities: not Other Significant Accounting Policies The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number: Policy Note Fair value measurements 5 Earnings per share 9 Share-based compensation 10 Reportable segments 12 Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, Revenue from Contracts with Customers 606 July 1, 2018, 606 July 1, 2018 606, not 605, Revenue Recognition ASC 606 not ASC 606 ASC 605 In January 2016, No. 2016 01 Recognition and Measurement of Financial Assets and Financial Liabilities no 2016 01 July 1, 2018 $54.3 $35.4 $8.3 $27.1 2019. 2016 01, July 1, 2018 $12.3 $2.9 nine March 31, 2019 2016 01 In February 2018, No. 2018 02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income 2017. December 15, 2018, July 1, 2019. 2018 02 July 1, 2018. $2.4 2018 02 2016 01 The following table presents a summary of cumulative effect adjustments to retained earnings due to the adoption of new accounting standards on July 1, 2018 Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780 In January 2017, No. 2017 01, Clarifying the Definition of a Business July 1, 2018, In August 2017, No. 2017 - 12, Targeted Improvements to Accounting for Hedging Activities December 15, 2018, July 1, 2019. 2017 12 October 1, 2018, 5. not Pronouncements Issued but Not Yet Adopted In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, July 1, 2019. Leases (Topic 842 ASU No. 2018 10 ASU 2019 01 ASU 2018 11 not 2018 11 Leases (Topic 842 not $82 In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 ), Measurement of Credit Losses on Financial Instruments December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not December 15, 2019, July 1, 2020 may first 2018 15

Note 2 - Revenue Recognition

Note 2 - Revenue Recognition	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 2 . Revenue Recognition: Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. The vast majority of service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no not not not not not third third The Company has elected the exemption to not one not June 30, 2019. Contracts with customers that contain instruments may Payment terms for shipments to end-users are generally net 30 may 30 90 Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one one June 30, 2019 not Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of June 30, 2019 June 30, 2018 $10.4 $9.3 June 30, 2018 June 30, 2019 $7.0 . C one Any claims for credit or return of goods must be made within 10 not Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented. Revenue by type is as follows: Year ended June 30, 2019 2018 2017 Consumables $ 588,979 $ 534,738 $ 476,541 Instruments 67,538 61,784 47,751 Services 38,050 34,137 23,652 Total product and services revenue, net 694,567 $ 630,659 547,944 Royalty revenues 19,439 12,334 15,059 Total revenues, net $ 714,006 $ 642,993 $ 563,003 Revenue by geography is as follows: Year Ended June 30, 2019 2018 2017 Net sales: United States $ 391,191 $ 346,293 $ 313,195 EMEA, excluding U.K. 155,821 148,599 125,126 U.K. 34,975 33,704 28,401 APAC, excluding Greater China 52,913 48,392 41,463 Greater China 57,799 47,950 39,078 Rest of world 21,307 18,055 15,740 Total external sales $ 714,006 $ 642,993 $ 563,003

Note 3 - Supplemental Balance S

Note 3 - Supplemental Balance Sheet and Cash Flow Information	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 3. Supplemental Balance Sheet and Cash Flow Information: Available-For-Sale Investments: The fair value of the Company's available-for-sale investments as of June 30, 2019 June 30, 2018 $38.2 $54.3 to year-over-year decreases in the stock price of CCXI, from $13.17 June 30, 2018 $9.30 June 30, 2019 $16.1 $18.8 June 30, 2019 2018. Inventories: Inventories consist of (in thousands): June 30, 2019 201 8 Raw materials $ 40,913 $ 30,956 Finished goods (1) 53,376 54,692 Inventories, net $ 94,289 $ 85,648 ( 1 $3,239 June 30, 2019 12 Property and Equipment: Property and equipment consist of (in thousands): June 30, 201 9 201 8 Cost: Land $ 7,065 $ 7,065 Buildings and improvements 175,019 170,110 Machinery, equipment and other 124,233 107,625 Property and equipment 306,317 284,800 Accumulated depreciation and amortization (152,278 ) (139,452 ) Property and equipment, net $ 154,039 $ 145,348 Intangibles assets were comprised of the following (in thousands): June 30, Useful Life (years) 201 9 201 8 Developed technology 9 - 15 $ 435,679 $ 305,303 Trade names 2 - 20 147,296 89,608 Customer relationships 7 - 16 214,320 212,228 Patents 10 2,133 1,401 Intangible assets 799,428 608,540 Accumulated amortization (219,999 ) (162,208 ) Intangibles assets, net $ 579,429 $ 446,332 Changes to the carrying amount of net intangible assets consist of (in thousands): June 30, 201 9 201 8 Beginning balance $ 446,332 $ 452,042 Acquisitions (Note 4) 191,956 40,673 Other additions 633 908 Amortization expense (58,715 ) (47,076 ) Currency translation (777 ) (215 ) Ending balance $ 579,429 $ 446,332 Amortization expense related to technologies included in cost of sales was $33.3 $25.3 $23.1 2019, 2018, 2017, $25.4 $21.6 $21.3 2019, 2018, 2017 The estimated future amortization expense for intangible assets as of June 30, 2019 2020 $ 59,905 2021 59,557 2022 57,905 2023 56,031 2024 53,464 Thereafter 292,567 Total $ 579,429 Changes in goodwill by reportable segment and in total consist of (in thousands): Protein Sciences Diagnostics & Genomics Total June 30, 2017 $ 331,789 $ 247,237 $ 579,026 Acquisitions (Note 4) 16,186 2,910 19,096 Currency translation (56 ) (176 ) (232 ) June 30, 2018 $ 347,918 $ 249,972 $ 597,890 Acquisitions (Note 4) 30,939 105,362 136,301 Currency translation (1,450 ) (74 ) (1,524 ) June 30, 2019 $ 377,407 $ 355,260 $ 732,667 Other Assets: Other assets consist of (in thousands): June 30, 201 9 201 8 Investments $ - $ 2,606 Other 5,668 2,660 Other long-term assets $ 5,668 $ 5,266 As of June 30, 2019, $5.7 $5.3 June 30, 2018. $3.2 June 30, 2019 12 4 June 30, 2018 June 30, 2019 12 Supplemental Cash Flow Information: Supplemental cash flow information was as follows (in thousands): Year Ended June 30, 201 9 201 8 201 7 Income taxes paid $ 36,814 $ 35,076 $ 42,900 Interest paid 21,497 9,844 7,452 Non-cash activities: Acquisition-related liabilities (1) 12,600 1,396 32,856 ( 1 4 5.

Note 4 - Acquisitions

Note 4 - Acquisitions	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 4 . Acquisitions: We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred. 2019 Acquisitions Quad Technologies On July 2, 2018, $20.5 $51.0 not first 2019. fourth 2019. Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 36 $ 36 Equipment and other long-term assets 284 (56 ) 228 Intangible assets: Developed technology 20,000 (7,744 ) 12,256 Goodwill 9,790 4,691 14,481 Total assets acquired 30,110 (3,109 ) 27,001 Liabilities 765 (469 ) 296 Deferred income taxes, net 3,741 (2,798 ) 943 Net assets acquired $ 25,604 $ 158 $ 25,762 Cash paid, net of cash acquired $ 20,404 $ 58 $ 20,462 Fair value of contingent consideration 5,200 100 5,300 Net assets acquired $ 25,604 $ 158 $ 25,762 As summarized in the table, there were adjustments totaling $4.7 2019 14 not Exosome Diagnostics On August 1, 2018, $251.6 $325.0 ● Up to $250 2020 $45 $58 ● Up to $45 2022 $54 $70 ● Up to $30 2022 $150 $190 The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’ product portfolio and the expected revenue growth from increased market penetration. The goodwill is not first 2019. fourth 2019. Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 5,118 (2,507 ) $ 2,611 Equipment and other long-term assets 2,212 - 2,212 Intangible assets: Developed technology 180,000 (75,000 ) 105,000 Trade name - 58,000 58,000 Customer relationships - 2,300 2,300 Goodwill 96,592 8,770 105,362 Total assets acquired 283,922 (8,437 ) 275,485 Liabilities 2,624 1,092 3,716 Deferred income taxes, net 27,673 (11,327 ) 16,346 Net assets acquired $ 253,625 $ 1,798 $ 255,423 Cash paid, net of cash acquired $ 251,825 $ (202 ) $ 251,623 Fair value of contingent consideration 1,800 2,000 3,800 Net assets acquired $ 253,625 $ 1,798 $ 255,423 As summarized in the table, there were adjustments totaling $8.8 $58.0 $75.0 $2.0 $2.3 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multiperiod excess earnings method to calculate the fair value of assets purchased. The preliminary amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Preliminary amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The preliminary amortization periods for intangible assets acquired in fiscal 2019 15 14 not B-MoGen Biotechnologies On June 4, 2019, $17.5 $38.0 $1.4 $3.7 not fourth 2019. not second 2020 Preliminary Allocation at Acquisition Date Current assets, net of cash $ 504 Equipment and other long-term assets 269 Intangible assets: Developed technology 14,000 Customer relationships 400 Goodwill 16,457 Total assets acquired 31,630 Liabilities 211 Deferred income taxes, net 3,377 Net assets acquired $ 28,042 Cash paid, net of cash acquired $ 17,448 Fair value of contingent consideration 5,500 Fair value of historical investment in B-MoGen 5,094 Net assets acquired $ 28,042 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The preliminary amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2019 14 not 2018 Acquisitions Trevigen On September 5, 2017 $10.6 not first 2018. Atlanta Biologicals On January 2, 2018 $51.3 not third 2018. 2018. Tangible assets acquired in the acquisition, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2018 13 12 15 not Eurocell Diagnostics On February 1, 2018, $7.3 $6.0 $1.3 February 1, 2019. not third 2018. 2018. Tangible assets acquired, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to customer relationships was based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. Amortization expense related customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships acquired in fiscal 2018 7 not 2017 Acquisitions Advanced Cell Diagnostics (ACD) On August 1, 2016, $258.0 $75.0 ● $25.0 2016 $30.0 ● an additional $50.0 2017 $45.0 The Company paid approximately $247.0 $11.0 18 March 31, 2018. $3.6 $11.0 $7.4 June 30, 2017. During the third 2017, 2016 third 2018, 2017 4 June 30, 2018 2017. The goodwill recorded as a result of the ACD acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not first 2017. As previously disclosed, ACD was acquired on August 1, 2016. 2016. not not 2016. Year Ended June 30, 2017 2016 Net sales $ 564,220 $ 523,840 Net income 99,380 110,536 Space Import-Export, Srl On July 1, 2016, $9.0 $6.7 $2.3 first 2018. not first 2017. Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not The aggregate purchase price of the acquisitions was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the fiscal year 2018 2017 Trevigen Atlanta Biologicals Eurocell Diagnostics ACD Space Current assets, net of cash $ 1,662 $ 15,722 $ 512 $ 15,824 $ 2,128 Equipment and other long-term assets 53 4,901 188 6,569 159 Intangible assets: Developed technology 5,100 23,000 - 150,000 - Trade name 160 2,300 - 21,900 - Customer relationships 260 3,600 6,272 6,300 6,769 Goodwill 5,991 10,195 2,910 143,967 3,517 Total assets acquired 13,226 59,718 9,882 344,560 12,573 Liabilities 387 90 483 4,179 1,445 Deferred income taxes, net 2,195 8,354 2,070 52,743 2,125 Net assets acquired $ 10,644 $ 51,274 $ 7,329 $ 287,638 $ 9,003 Cash paid, net of cash acquired 10,644 51,274 $ 5,933 $ 247,038 $ 6,747 Consideration payable - - 1,396 3,600 2,256 Contingent consideration payable - - - 37,000 - Net assets acquired $ 10,644 $ 51,274 $ 7,329 $ 287,638 $ 9,003 Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of good sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Note 5. Fair Value Measurements: The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three 1 2 not 3 one 3 may The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 201 9 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 38,219 $ 38,219 $ - $ - Certificates of deposit (2) 26,928 26,928 - - Total Assets $ 65,147 $ 65,147 $ - $ - Liabilities Contingent consideration $ 12,600 $ - $ - $ 12,600 Derivative instruments - cash flow hedges 12,458 - 12,458 - Total Liabilities $ 25,058 $ - $ 12,458 $ 12,600 Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 201 8 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 54,286 $ 54,286 $ - $ - Certificates of deposit (2) 5,478 5,478 - - Total Assets $ 59,764 $ 59,764 $ - $ - Liabilities Contingent consideration $ - $ - $ - $ - ( 1 June 30, 2019 June 30, 2018 $18.8 ( 2 one Fair value measurements of available for sale securities Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 Fair value measurements of derivative instruments In October 2018, 6 $380 not June 30, 2019. 2 Fair value measurements of contingent consideration In connection with the ExosomeDx, Quad, and B-Mogen acquisitions the Company is required to make contingent consideration payments of up to $325.0 $51.0 $38.0 $14.6 $3.8 $5.3 $5.5 4. 3 In fiscal 2018, $88.5 $88.5 $61.9 $26.6 The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 June 30, 201 9 201 8 Fair value at the beginning of period $ - $ 68,400 Purchase price contingent consideration (Note 4) 14,600 - Payments - (88,500 ) Change in fair value of contingent consideration (2,000 ) 20,100 Contingent consideration payable $ 12,600 $ - Fair value measurements of other financial instruments Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items. Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility approximates fair value because our interest rate is variable and reflects current market rates.

Note 6 - Debt and Other Financi

Note 6 - Debt and Other Financing Arrangements	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6 . Debt and Other Financing Arrangements: On August 1, 2018, $600.0 $200.0 $250.0 may 20 $12.5 2020. The Credit Agreement matures on August 1, 2023 August 1, 2018 $250.0 $330.0 June 30, 2019, $505.2

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 7. Commitments and Contingencies: The Company leases office and warehouse space, vehicles and various office equipment under operating leases. At June 30, 2019, one 2020 $ 13,707 2021 13,469 2022 13,154 2023 12,716 2024 11,392 Thereafter 51,895 Total $ 116,333 Total rent expense was approximately $12.9 $10.8 $9.8 June 30, 2019, 2018, 2017, The Company is routinely subject to claims and involved in legal actions which are incidental to the business of the Company. Although it is difficult to predict the ultimate outcome of these matters, management believes that any ultimate liability will not

Note 8 - Supplemental Equity an

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss): Supplemental Equity The Company has declared cash dividends per share of $1.28 June 30, 2019, June 30, 2018, June 30, 2017. June 30, 2019, 95,000 $162.15. 2019, Accumulated Other Comprehensive Income (loss) Changes in accumulated other comprehensive income (loss), net of tax, at June 30 Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Unrealized Gains (Losses) on Derivatives Instruments Total Balance June 30, 2016 $ (5,542 ) (64,863 ) - $ (70,405 ) Other comprehensive income (loss) before reclassifications 24,531 (3,061 ) - 21,470 Balance June 30, 2017 $ 18,989 (67,924 ) - $ (48,935 ) Other comprehensive income (loss) before reclassifications 18,108 (1,572 ) - 16,536 Amounts reclassified from accumulated other comprehensive loss to income (12,415 ) - - (12,415 ) Balance June 30, 2018 $ 24,682 (69,496 ) - $ (44,814 ) Cumulative effect adjustment for adoption for ASU 2018-02 (1) 2,371 - - 2,371 Cumulative effect adjustment for adoption for ASU 2016-01 (1) (27,053 ) - - (27,053 ) Other comprehensive income (loss) before reclassifications (2) - (4,487 ) (9,537 ) (14,024 ) Balance June 30, 2019 $ - (73,983 ) (9,537 ) $ (83,521 ) ( 1 1 2016 01 2018 02. ( 2 October 31, 2019. $1,748 $9,537 12 June 30, 2019.

Note 9 - Earnings Per Share

Note 9 - Earnings Per Share	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9. Earnings Per Share: The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): Year Ended June 30, 2019 201 8 201 7 Earnings per share – basic: Net income $ 96,072 $ 126,150 $ 76,086 Income allocated to participating securities (105 ) (108 ) (65 ) Income available to common shareholders $ 95,967 $ 126,042 $ 76,021 Weighted-average shares outstanding – basic 37,781 37,476 37,313 Earnings per share – basic $ 2.54 $ 3.36 $ 2.04 Earnings per share – diluted: Net income $ 96,072 $ 126,150 $ 76,086 Income allocated to participating securities (105 ) (108 ) (65 ) Income available to common shareholders $ 95,967 $ 126,042 $ 76,021 Weighted-average shares outstanding – basic 37,781 37,476 37,313 Dilutive effect of stock options and restricted stock units 1,111 579 187 Weighted-average common shares outstanding – diluted 38,892 38,055 37,500 Earnings per share – diluted $ 2.47 $ 3.31 $ 2.03 Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 1.3 0.9 2.0 June 30, 2019, 2018 2017,

Note 10 - Share-based Compensat

Note 10 - Share-based Compensation and Other Benefit Plans	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 10. Share-based Compensation and Other Benefit Plans: The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. Equity incentive plan: The Company's Second Amended and Restated 2010 2010 7.5 2010 June 30, 2019, 2.6 2010 2010 ten 2010 2010 2010 2010 1998 1998 2010 1998 June 30, 2019 2010 1998 re 3.6 20,000, April 26, 2018 $8.3 2018 The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used: Year Ended June 30, 201 9 201 8 201 7 Dividend yield 0.74% 1.1% 1.2% Expected volatility 20% - 23% 20% - 21% 21% - 24% Risk-free interest rates 2.5% - 3.0% 1.7% - 2.8% 1.0% - 1.9% Expected lives (years) 4.1 4.7 4.7 The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted. Stock option activity under the Plans for the three June 30, 2019, Number of Shares (in thousands) Weighted Aggregate (millions) Weighted Average Contractual Life (years) Outstanding at June 30, 2016 1,819 $ 91.91 Granted 1,135 107.42 Forfeited (70 ) 99.11 Exercised (63 ) 71.81 Outstanding at June 30, 2017 2,821 $ 98.42 Granted 1,087 120.67 Forfeited (252 ) 86.62 Exercised (204 ) 111.51 Outstanding at June 30, 2018 3,452 $ 105.17 Granted 917 173.89 Forfeited (330 ) 129.93 Exercised (383 ) 95.29 Outstanding at June 30, 2019 3,656 $ 121.16 $ 319.3 4.45 Exercisable at June 30, 2017: 843 82.93 Exercisable at June 30, 2018: 1,151 90.75 Exercisable at June 30, 2019: 1,467 98.70 $ 161 3.33 The weighted average fair value of options granted during fiscal 2019, 2018 2017 $34.66, $22.07 $18.21 2019, 2018 2017 $159.0 $10.6 $2.3 2019, 2018 2017 $31.7 $8.8 $5.0 Restricted common stock activity under the Plans for the three June 30, 2019, Number of Shares (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (years) Unvested at June 30, 2016 23 $ 98.03 Granted 24 104.94 Vested (15 ) 92.62 Forfeited - - Unvested at June 30, 2017 32 $ 105.80 Granted 20 125.05 Vested (17 ) 104.66 Forfeited - - Unvested at June 30, 2018 35 $ 117.39 Granted 15 177.93 Vested (20 ) 116.76 Forfeited - - Unvested at June 30, 2019 30 $ 117.39 5.88 The total fair value of restricted shares that vested was $2.3 2019, $1.7 2018, $1.4 2017. Restricted stock unit activity under the Plans for the three June 30, 2019, Number of Units (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (years) Outstanding at June 30, 2016 59 $ 100.40 Granted 65 109.36 Vested (9 ) 92.94 Forfeited (4 ) 98.04 Outstanding at June 30, 2017 111 $ 106.39 Granted 71 129.99 Vested (16 ) 95.46 Forfeited (18 ) 115.01 Outstanding at June 30, 2018 148 $ 117.95 Granted 56 170.96 Vested (28 ) 110.86 Forfeited (36 ) 143.72 Outstanding at June 30, 2019 139 $ 134.17 5.17 The total fair value of restricted stock units that vested was $3.1 2019, $1.6 2018, $0.9 2017. three Stock-based compensation cost of $32.3 $28 .2 $14.6 2019, 2018 2017, was $0.4 $0.5 2018, 2017, June 30, 2019, s $26.6 2020 2022 3% 2.0 Employee stock purchase plan: 2015, 2014 October 30, 2014, 200,000 $0.5 $0.3 $0.2 2019, 2018 2017, Profit sharing and savings plans: 401 of $2.8 $2.5 $2.2 June 30, 2019, 2018, 2017, $1.4 $1.4, $0.8 June 30, 2019, 2018 2017, Performance incentive programs: In fiscal 2019, $9.3 618,898 11,279 25, 903 2018 2017, $7.2 $4.7 553,750 896,778 14,194 16,653 35,174 39,931

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 11. Income Taxes: Income before income taxes was comprised of the following (in thousands): Year Ended June 30, 201 9 201 8 201 7 Domestic $ 64,081 $ 81,557 $ 81,721 Foreign 47,934 44,395 30,240 Income before income taxes $ 112,015 $ 125,952 $ 111,961 The provision for income taxes consisted of the following (in thousands): Year Ended June 30, 201 9 201 8 201 7 Taxes on income consist of: Currently tax provision: Federal $ 16,090 $ 28,416 $ 28,462 State 544 5,315 4,051 Foreign 13,329 11,983 8,212 Total current tax provision 29,963 45,714 40,725 Deferred tax provision: Federal (6,903 ) (40,378 ) (901 ) State (3,977 ) (1,381 ) (968 ) Foreign (3,142 ) (4,154 ) (2,981 ) Total deferred tax provision (14,021 ) (45,912 ) (4,850 ) Total income tax provision $ 15,942 $ (198 ) $ 35,875 The Company’s effective income tax rate for fiscal 2019 14.2% 0.2% 2019 2018 $12.7 $34.4 2019 2018, The Company's discrete tax benefits in fiscal 2019 $7.2 $3.2 $2.0 third In fiscal 2018, $34.4 2018 $33.0 $36.5 $3.3 2018 $2.2 $4.2 not On December 22, 2017, 35% 21%, one 118” 2018 05 Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 118, one The end of the measurement period allowed under ASU 2018 05 December 31, 2018. may The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided (in thousands): Year Ended June 30, 201 9 201 8 201 7 Income tax expense at federal statutory rate 21.0 % 28.1 % 35.0 % State income taxes, net of federal benefit 0.8 % 2.5 % 1.9 % Qualified production activity deduction - % (2.4 )% (3.4 )% Research and development tax credit (1.6 )% (1.4 )% (1.4 )% Contingent consideration adjustment (0.4 )% 3.3 % 4.1 % Foreign tax rate differences 0.2 % (3.5 )% (4.6 )% Option exercises (5.8 )% (1.8 )% - % Domestic tax legislation changes 1.7 % (26.2 )% - % State apportionment changes (2.3 )% - - Other, net 0.6 % 1.2 % 0.4 % Effective tax rate 14.2 % (0.2 )% 32.0 % Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands): June 30 201 9 201 8 Inventory $ 7,743 $ 5,873 Net operating loss carryovers 33,294 15,938 Tax credit carryovers 9,640 7,029 Excess tax basis in equity investments 3,433 2,813 Deferred compensation 10,333 7,806 Derivative - cash flow hedge 2,921 - Other 5,207 3,864 Valuation allowance (6,974 ) (2,978 ) Deferred tax assets 65,597 40,345 Net unrealized gain on available-for-sale investments (4,542 ) (8,384 ) Intangible asset amortization (141,998 ) (111,247 ) Depreciation (8,371 ) (6,349 ) Other (440 ) (658 ) Deferred tax liabilities (155,351 ) (126,638 ) Net deferred tax liabilities $ (89,754 ) $ (86,293 ) A deferred tax valuation allowance is required when it is more likely than not not June 30, 2019 $7.0 $4.0 2019 As of June 30, 2019, $7.0 not not As of June 30, 2019, $98.2 $137.4 not 382. June 30, 2019, $13.6 million. The net operating loss carryforwards expire between fiscal 2020 2035. $28.2 , net of the valuation allowance discussed above, related to the net operating loss carryovers. As of June 30, 2019, $5.2 million and $4.4 million, respectively. The federal tax credit carryforwards expire between 2028 2038. no $7.7 million, net of the valuation allowance discussed above, related to the tax credit carryovers. The Company has not $160 2018 one No We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation. In addition, we anticipate that further guidance from the IRS and US Treasury related to the Tax Act could impact the amount of any related taxes. Therefore, it is not The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands): Year Ended June 30, 201 9 201 8 201 7 Beginning balance $ 1,947 $ 1,747 $ 1,480 Additions due to acquisitions 900 628 Additions for tax positions of current year 2,185 35 13 Closure of tax years (374 ) Tax reform 165 Ending balances $ 5,032 $ 1,947 $ 1,747 The Company does not twelve 2016 three five one

Note 12 - Segment Information

Note 12 - Segment Information	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12. Segment Information: The Company has two The Company's Protein Sciences segment is comprised of the Reagent Sol utions and the Analytical Solutions operating segment. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No 10% June 30, 2019 2018, 2017. The Company's Diagnostics and Genomics is comprised of the Diagnostics, Genomics, and Exosome operating segments. The Diagnostics division consists of the Diagnostics operating segment and develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits, and the Genomics division consists of the Genomics and Exosome operating segments and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No 10% June 30, 2019, 2018, 2017. There are no Following is financial information relating to the operating segments (in thousands): Year Ended June 30, 201 9 201 8 201 7 Net sales: Protein Sciences $ 543,159 $ 482,378 $ 419,365 Diagnostics and Genomics 171,674 161,151 143,742 Intersegment (827 ) (536 ) (104 ) Consolidated net sales $ 714,006 $ 642,993 $ 563,003 Operating Income: Protein Sciences $ 240,919 $ 209,880 $ 184,095 Diagnostics and Genomics 10,079 35,496 29,291 Segment operating income 250,998 245,376 213,386 Costs recognized upon sale of acquired inventory (3,739 ) (2,455 ) (3,037 ) Amortization of acquired intangible assets (58,550 ) (46,983 ) (44,393 ) Acquisition related expenses (2,282 ) (24,429 ) (25,789 ) Restructuring costs - (376 ) - Stock-based compensation (33,057 ) (28,240 ) (14,631 ) Corporate general, selling and administrative expenses (6,651 ) (6,715 ) (4,952 ) Consolidated operating income $ 146,719 $ 136,178 $ 120,584 The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by reportable segment has not not not not The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. 2. Year Ended June 30, 201 9 201 8 201 7 Consumables revenue - Protein Sciences $ 430,655 $ 384,350 $ 341,611 Consumables revenue - Diagnostics and Genomics 158,324 150,388 134,930 Total consumable revenue $ 588,979 $ 534,738 $ 476,541 The following is financial information relating to geographic areas (in thousands): Year ended June 30, Long-lived assets: 201 9 201 8 United States and Canada $ 138,016 $ 129,360 Europe 14,439 14,597 Asia 1,584 1,391 Total long-lived assets $ 154,039 $ 145,348 Intangible assets: United States and Canada $ 556,951 $ 417,430 Europe 16,637 21,386 Asia 5,841 7,516 Total intangible assets $ 579,429 $ 446,332 Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

Note 13 - Quarterly Financial D

Note 13 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Quarterly Financial Information [Text Block]	Note 13. Quarterly Financial Data (unaudited): (in thousands, except per share data) 2019 First Quarter Second Quarter Third Quarter Fourth Quarter Year Net sales $ 162,970 $ 174,510 $ 184,861 $ 191,664 $ 714,006 Cost of sales $ 55,367 $ 61,492 $ 60,251 $ 63,405 $ 240,515 Net earnings $ 17,403 $ 17,556 $ 44,654 $ 16,459 $ 96,072 Earnings per common share: Basic $ 0.46 $ 0.46 $ 1.18 $ 0.43 $ 2.54 Diluted $ 0.45 $ 0.45 $ 1.15 $ 0.42 $ 2.47 Weighted average common shares outstanding: Basic 37,697 37,766 37,772 37,881 37,781 Diluted 38,813 38,748 38,861 39,135 38,892 (in thousands, except per share data) 2018 First Quarter Second Quarter Third Quarter Fourth Quarter Year Net sales $ 144,613 $ 154,153 $ 163,973 $ 180,254 $ 642,993 Cost of sales $ 46,745 $ 52,319 $ 53,712 $ 58,074 $ 210,850 Net earnings (1) $ 15,863 $ 48,847 $ 19,738 $ 41,701 $ 126,150 Earnings per common share: Basic $ 0.42 $ 1.30 $ 0.53 $ 1.09 $ 3.36 Diluted $ 0.42 $ 1.29 $ 0.52 $ 1.07 $ 3.31 Weighted average common shares outstanding: Basic 37,376 37,449 37,503 37,585 37,476 Diluted 37,705 37,926 38,142 38,347 38,055 ( 1 ) not

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 14. Subsequent Events: None

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates:
Consolidation, Policy [Policy Text Block]	Principles of consolidation:
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign financial statements:
Revenue [Policy Text Block]	Revenue recognition: ASC 606 Revenue from Contracts with Customers July 1, 2018 606 606 Recently Adopted Accounting Pronouncements 1 606 2 ASC 606
Research and Development Expense, Policy [Policy Text Block]	Research and development:
Advertising Cost [Policy Text Block]	Advertising costs: $4.1 $3.8 $4.5 2019, 2018, 2017
Income Tax, Policy [Policy Text Block]	Income taxes: not fifty See Note 11
Comprehensive Income, Policy [Policy Text Block]	Comprehensive income: not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents: three
Marketable Securities, Policy [Policy Text Block]	Available-for-sale investments: three six 2019 2018 02 July 1, 2018, Recently Adopted Accounting Pronouncements 1. 2018 2017.
Accounts Receivable [Policy Text Block]	Trade accounts receivable: not
Inventory, Policy [Policy Text Block]	Inventories: For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no ASC 330
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment: 3 5 5 40
Contingent Consideration, Policy [Policy Text Block]	Contingent Consideration: may
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangibles assets: 1 20 no
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of long-lived assets and amortizable intangibles: may not not 1 2 3 not The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may No no 2017, 2018, 2019. Impairment of goodwill: fourth not 1 2 3 4 To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one 2019 Goodwill Impairment Analyses At the beginning of the quarter ended March 31, 2019, Because our quantitative analysis performed as of January 1, 2019 not The quantitative assessments completed as of January 1, 2019 The Company has elected April 1 June 30. April 1. not In conducting our annual goodwill impairment test, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not Based on its annual analysis, the Company determined there was no no June 30, 2019 2018 2017 Goodwill Impairment Analyses In completing our 2018 2017 2017 04, The quantitative assessment completed as of June 30, 2018 2017 There has been no 350 July 1, 2002.
Equity Method Investments [Policy Text Block]	Investments in unconsolidated entities: not
Other Significant Accounting Policies [Policy Text Block]	Other Significant Accounting Policies The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number: Policy Note Fair value measurements 5 Earnings per share 9 Share-based compensation 10 Reportable segments 12
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, Revenue from Contracts with Customers 606 July 1, 2018, 606 July 1, 2018 606, not 605, Revenue Recognition ASC 606 not ASC 606 ASC 605 In January 2016, No. 2016 01 Recognition and Measurement of Financial Assets and Financial Liabilities no 2016 01 July 1, 2018 $54.3 $35.4 $8.3 $27.1 2019. 2016 01, July 1, 2018 $12.3 $2.9 nine March 31, 2019 2016 01 In February 2018, No. 2018 02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income 2017. December 15, 2018, July 1, 2019. 2018 02 July 1, 2018. $2.4 2018 02 2016 01 The following table presents a summary of cumulative effect adjustments to retained earnings due to the adoption of new accounting standards on July 1, 2018 Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780 In January 2017, No. 2017 01, Clarifying the Definition of a Business July 1, 2018, In August 2017, No. 2017 - 12, Targeted Improvements to Accounting for Hedging Activities December 15, 2018, July 1, 2019. 2017 12 October 1, 2018, 5. not Pronouncements Issued but Not Yet Adopted In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, July 1, 2019. Leases (Topic 842 ASU No. 2018 10 ASU 2019 01 ASU 2018 11 not 2018 11 Leases (Topic 842 not $82 In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 ), Measurement of Credit Losses on Financial Instruments December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not December 15, 2019, July 1, 2020 may first 2018 15

Note 1 - Description of Busin_2

Note 1 - Description of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780

Note 2 - Revenue Recognition (T

Note 2 - Revenue Recognition (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year ended June 30, 2019 2018 2017 Consumables $ 588,979 $ 534,738 $ 476,541 Instruments 67,538 61,784 47,751 Services 38,050 34,137 23,652 Total product and services revenue, net 694,567 $ 630,659 547,944 Royalty revenues 19,439 12,334 15,059 Total revenues, net $ 714,006 $ 642,993 $ 563,003 Year Ended June 30, 2019 2018 2017 Net sales: United States $ 391,191 $ 346,293 $ 313,195 EMEA, excluding U.K. 155,821 148,599 125,126 U.K. 34,975 33,704 28,401 APAC, excluding Greater China 52,913 48,392 41,463 Greater China 57,799 47,950 39,078 Rest of world 21,307 18,055 15,740 Total external sales $ 714,006 $ 642,993 $ 563,003

Note 3 - Supplemental Balance_2

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2019 201 8 Raw materials $ 40,913 $ 30,956 Finished goods (1) 53,376 54,692 Inventories, net $ 94,289 $ 85,648
Property, Plant and Equipment [Table Text Block]	June 30, 201 9 201 8 Cost: Land $ 7,065 $ 7,065 Buildings and improvements 175,019 170,110 Machinery, equipment and other 124,233 107,625 Property and equipment 306,317 284,800 Accumulated depreciation and amortization (152,278 ) (139,452 ) Property and equipment, net $ 154,039 $ 145,348
Schedule of Intangible Assets and Goodwill [Table Text Block]	June 30, Useful Life (years) 201 9 201 8 Developed technology 9 - 15 $ 435,679 $ 305,303 Trade names 2 - 20 147,296 89,608 Customer relationships 7 - 16 214,320 212,228 Patents 10 2,133 1,401 Intangible assets 799,428 608,540 Accumulated amortization (219,999 ) (162,208 ) Intangibles assets, net $ 579,429 $ 446,332
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 201 9 201 8 Beginning balance $ 446,332 $ 452,042 Acquisitions (Note 4) 191,956 40,673 Other additions 633 908 Amortization expense (58,715 ) (47,076 ) Currency translation (777 ) (215 ) Ending balance $ 579,429 $ 446,332
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2020 $ 59,905 2021 59,557 2022 57,905 2023 56,031 2024 53,464 Thereafter 292,567 Total $ 579,429
Schedule of Goodwill [Table Text Block]	Protein Sciences Diagnostics & Genomics Total June 30, 2017 $ 331,789 $ 247,237 $ 579,026 Acquisitions (Note 4) 16,186 2,910 19,096 Currency translation (56 ) (176 ) (232 ) June 30, 2018 $ 347,918 $ 249,972 $ 597,890 Acquisitions (Note 4) 30,939 105,362 136,301 Currency translation (1,450 ) (74 ) (1,524 ) June 30, 2019 $ 377,407 $ 355,260 $ 732,667
Schedule of Other Assets, Noncurrent [Table Text Block]	June 30, 201 9 201 8 Investments $ - $ 2,606 Other 5,668 2,660 Other long-term assets $ 5,668 $ 5,266
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Year Ended June 30, 201 9 201 8 201 7 Income taxes paid $ 36,814 $ 35,076 $ 42,900 Interest paid 21,497 9,844 7,452 Non-cash activities: Acquisition-related liabilities (1) 12,600 1,396 32,856

Note 4 - Acquisitions (Tables)

Note 4 - Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 36 $ 36 Equipment and other long-term assets 284 (56 ) 228 Intangible assets: Developed technology 20,000 (7,744 ) 12,256 Goodwill 9,790 4,691 14,481 Total assets acquired 30,110 (3,109 ) 27,001 Liabilities 765 (469 ) 296 Deferred income taxes, net 3,741 (2,798 ) 943 Net assets acquired $ 25,604 $ 158 $ 25,762 Cash paid, net of cash acquired $ 20,404 $ 58 $ 20,462 Fair value of contingent consideration 5,200 100 5,300 Net assets acquired $ 25,604 $ 158 $ 25,762 Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 5,118 (2,507 ) $ 2,611 Equipment and other long-term assets 2,212 - 2,212 Intangible assets: Developed technology 180,000 (75,000 ) 105,000 Trade name - 58,000 58,000 Customer relationships - 2,300 2,300 Goodwill 96,592 8,770 105,362 Total assets acquired 283,922 (8,437 ) 275,485 Liabilities 2,624 1,092 3,716 Deferred income taxes, net 27,673 (11,327 ) 16,346 Net assets acquired $ 253,625 $ 1,798 $ 255,423 Cash paid, net of cash acquired $ 251,825 $ (202 ) $ 251,623 Fair value of contingent consideration 1,800 2,000 3,800 Net assets acquired $ 253,625 $ 1,798 $ 255,423 Preliminary Allocation at Acquisition Date Current assets, net of cash $ 504 Equipment and other long-term assets 269 Intangible assets: Developed technology 14,000 Customer relationships 400 Goodwill 16,457 Total assets acquired 31,630 Liabilities 211 Deferred income taxes, net 3,377 Net assets acquired $ 28,042 Cash paid, net of cash acquired $ 17,448 Fair value of contingent consideration 5,500 Fair value of historical investment in B-MoGen 5,094 Net assets acquired $ 28,042
Business Acquisition, Pro Forma Information [Table Text Block]	Year Ended June 30, 2017 2016 Net sales $ 564,220 $ 523,840 Net income 99,380 110,536
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Trevigen Atlanta Biologicals Eurocell Diagnostics ACD Space Current assets, net of cash $ 1,662 $ 15,722 $ 512 $ 15,824 $ 2,128 Equipment and other long-term assets 53 4,901 188 6,569 159 Intangible assets: Developed technology 5,100 23,000 - 150,000 - Trade name 160 2,300 - 21,900 - Customer relationships 260 3,600 6,272 6,300 6,769 Goodwill 5,991 10,195 2,910 143,967 3,517 Total assets acquired 13,226 59,718 9,882 344,560 12,573 Liabilities 387 90 483 4,179 1,445 Deferred income taxes, net 2,195 8,354 2,070 52,743 2,125 Net assets acquired $ 10,644 $ 51,274 $ 7,329 $ 287,638 $ 9,003 Cash paid, net of cash acquired 10,644 51,274 $ 5,933 $ 247,038 $ 6,747 Consideration payable - - 1,396 3,600 2,256 Contingent consideration payable - - - 37,000 - Net assets acquired $ 10,644 $ 51,274 $ 7,329 $ 287,638 $ 9,003

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 201 9 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 38,219 $ 38,219 $ - $ - Certificates of deposit (2) 26,928 26,928 - - Total Assets $ 65,147 $ 65,147 $ - $ - Liabilities Contingent consideration $ 12,600 $ - $ - $ 12,600 Derivative instruments - cash flow hedges 12,458 - 12,458 - Total Liabilities $ 25,058 $ - $ 12,458 $ 12,600 Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 201 8 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 54,286 $ 54,286 $ - $ - Certificates of deposit (2) 5,478 5,478 - - Total Assets $ 59,764 $ 59,764 $ - $ - Liabilities Contingent consideration $ - $ - $ - $ -
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	June 30, 201 9 201 8 Fair value at the beginning of period $ - $ 68,400 Purchase price contingent consideration (Note 4) 14,600 - Payments - (88,500 ) Change in fair value of contingent consideration (2,000 ) 20,100 Contingent consideration payable $ 12,600 $ -

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Lessee, Operating Lease, Disclosure [Table Text Block]	2020 $ 13,707 2021 13,469 2022 13,154 2023 12,716 2024 11,392 Thereafter 51,895 Total $ 116,333

Note 8 - Supplemental Equity _2

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Unrealized Gains (Losses) on Derivatives Instruments Total Balance June 30, 2016 $ (5,542 ) (64,863 ) - $ (70,405 ) Other comprehensive income (loss) before reclassifications 24,531 (3,061 ) - 21,470 Balance June 30, 2017 $ 18,989 (67,924 ) - $ (48,935 ) Other comprehensive income (loss) before reclassifications 18,108 (1,572 ) - 16,536 Amounts reclassified from accumulated other comprehensive loss to income (12,415 ) - - (12,415 ) Balance June 30, 2018 $ 24,682 (69,496 ) - $ (44,814 ) Cumulative effect adjustment for adoption for ASU 2018-02 (1) 2,371 - - 2,371 Cumulative effect adjustment for adoption for ASU 2016-01 (1) (27,053 ) - - (27,053 ) Other comprehensive income (loss) before reclassifications (2) - (4,487 ) (9,537 ) (14,024 ) Balance June 30, 2019 $ - (73,983 ) (9,537 ) $ (83,521 )

Note 9 - Earnings Per Share (Ta

Note 9 - Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended June 30, 2019 201 8 201 7 Earnings per share – basic: Net income $ 96,072 $ 126,150 $ 76,086 Income allocated to participating securities (105 ) (108 ) (65 ) Income available to common shareholders $ 95,967 $ 126,042 $ 76,021 Weighted-average shares outstanding – basic 37,781 37,476 37,313 Earnings per share – basic $ 2.54 $ 3.36 $ 2.04 Earnings per share – diluted: Net income $ 96,072 $ 126,150 $ 76,086 Income allocated to participating securities (105 ) (108 ) (65 ) Income available to common shareholders $ 95,967 $ 126,042 $ 76,021 Weighted-average shares outstanding – basic 37,781 37,476 37,313 Dilutive effect of stock options and restricted stock units 1,111 579 187 Weighted-average common shares outstanding – diluted 38,892 38,055 37,500 Earnings per share – diluted $ 2.47 $ 3.31 $ 2.03

Note 10 - Share-based Compens_2

Note 10 - Share-based Compensation and Other Benefit Plans (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended June 30, 201 9 201 8 201 7 Dividend yield 0.74% 1.1% 1.2% Expected volatility 20% - 23% 20% - 21% 21% - 24% Risk-free interest rates 2.5% - 3.0% 1.7% - 2.8% 1.0% - 1.9% Expected lives (years) 4.1 4.7 4.7
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares (in thousands) Weighted Aggregate (millions) Weighted Average Contractual Life (years) Outstanding at June 30, 2016 1,819 $ 91.91 Granted 1,135 107.42 Forfeited (70 ) 99.11 Exercised (63 ) 71.81 Outstanding at June 30, 2017 2,821 $ 98.42 Granted 1,087 120.67 Forfeited (252 ) 86.62 Exercised (204 ) 111.51 Outstanding at June 30, 2018 3,452 $ 105.17 Granted 917 173.89 Forfeited (330 ) 129.93 Exercised (383 ) 95.29 Outstanding at June 30, 2019 3,656 $ 121.16 $ 319.3 4.45 Exercisable at June 30, 2017: 843 82.93 Exercisable at June 30, 2018: 1,151 90.75 Exercisable at June 30, 2019: 1,467 98.70 $ 161 3.33
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Number of Shares (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (years) Unvested at June 30, 2016 23 $ 98.03 Granted 24 104.94 Vested (15 ) 92.62 Forfeited - - Unvested at June 30, 2017 32 $ 105.80 Granted 20 125.05 Vested (17 ) 104.66 Forfeited - - Unvested at June 30, 2018 35 $ 117.39 Granted 15 177.93 Vested (20 ) 116.76 Forfeited - - Unvested at June 30, 2019 30 $ 117.39 5.88 Number of Units (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (years) Outstanding at June 30, 2016 59 $ 100.40 Granted 65 109.36 Vested (9 ) 92.94 Forfeited (4 ) 98.04 Outstanding at June 30, 2017 111 $ 106.39 Granted 71 129.99 Vested (16 ) 95.46 Forfeited (18 ) 115.01 Outstanding at June 30, 2018 148 $ 117.95 Granted 56 170.96 Vested (28 ) 110.86 Forfeited (36 ) 143.72 Outstanding at June 30, 2019 139 $ 134.17 5.17

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended June 30, 201 9 201 8 201 7 Domestic $ 64,081 $ 81,557 $ 81,721 Foreign 47,934 44,395 30,240 Income before income taxes $ 112,015 $ 125,952 $ 111,961 Year Ended June 30, 201 9 201 8 201 7 Taxes on income consist of: Currently tax provision: Federal $ 16,090 $ 28,416 $ 28,462 State 544 5,315 4,051 Foreign 13,329 11,983 8,212 Total current tax provision 29,963 45,714 40,725 Deferred tax provision: Federal (6,903 ) (40,378 ) (901 ) State (3,977 ) (1,381 ) (968 ) Foreign (3,142 ) (4,154 ) (2,981 ) Total deferred tax provision (14,021 ) (45,912 ) (4,850 ) Total income tax provision $ 15,942 $ (198 ) $ 35,875
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended June 30, 201 9 201 8 201 7 Income tax expense at federal statutory rate 21.0 % 28.1 % 35.0 % State income taxes, net of federal benefit 0.8 % 2.5 % 1.9 % Qualified production activity deduction - % (2.4 )% (3.4 )% Research and development tax credit (1.6 )% (1.4 )% (1.4 )% Contingent consideration adjustment (0.4 )% 3.3 % 4.1 % Foreign tax rate differences 0.2 % (3.5 )% (4.6 )% Option exercises (5.8 )% (1.8 )% - % Domestic tax legislation changes 1.7 % (26.2 )% - % State apportionment changes (2.3 )% - - Other, net 0.6 % 1.2 % 0.4 % Effective tax rate 14.2 % (0.2 )% 32.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30 201 9 201 8 Inventory $ 7,743 $ 5,873 Net operating loss carryovers 33,294 15,938 Tax credit carryovers 9,640 7,029 Excess tax basis in equity investments 3,433 2,813 Deferred compensation 10,333 7,806 Derivative - cash flow hedge 2,921 - Other 5,207 3,864 Valuation allowance (6,974 ) (2,978 ) Deferred tax assets 65,597 40,345 Net unrealized gain on available-for-sale investments (4,542 ) (8,384 ) Intangible asset amortization (141,998 ) (111,247 ) Depreciation (8,371 ) (6,349 ) Other (440 ) (658 ) Deferred tax liabilities (155,351 ) (126,638 ) Net deferred tax liabilities $ (89,754 ) $ (86,293 )
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended June 30, 201 9 201 8 201 7 Beginning balance $ 1,947 $ 1,747 $ 1,480 Additions due to acquisitions 900 628 Additions for tax positions of current year 2,185 35 13 Closure of tax years (374 ) Tax reform 165 Ending balances $ 5,032 $ 1,947 $ 1,747

Note 12 - Segment Information (

Note 12 - Segment Information (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended June 30, 201 9 201 8 201 7 Net sales: Protein Sciences $ 543,159 $ 482,378 $ 419,365 Diagnostics and Genomics 171,674 161,151 143,742 Intersegment (827 ) (536 ) (104 ) Consolidated net sales $ 714,006 $ 642,993 $ 563,003 Operating Income: Protein Sciences $ 240,919 $ 209,880 $ 184,095 Diagnostics and Genomics 10,079 35,496 29,291 Segment operating income 250,998 245,376 213,386 Costs recognized upon sale of acquired inventory (3,739 ) (2,455 ) (3,037 ) Amortization of acquired intangible assets (58,550 ) (46,983 ) (44,393 ) Acquisition related expenses (2,282 ) (24,429 ) (25,789 ) Restructuring costs - (376 ) - Stock-based compensation (33,057 ) (28,240 ) (14,631 ) Corporate general, selling and administrative expenses (6,651 ) (6,715 ) (4,952 ) Consolidated operating income $ 146,719 $ 136,178 $ 120,584 Year Ended June 30, 201 9 201 8 201 7 Consumables revenue - Protein Sciences $ 430,655 $ 384,350 $ 341,611 Consumables revenue - Diagnostics and Genomics 158,324 150,388 134,930 Total consumable revenue $ 588,979 $ 534,738 $ 476,541 Year ended June 30, Long-lived assets: 201 9 201 8 United States and Canada $ 138,016 $ 129,360 Europe 14,439 14,597 Asia 1,584 1,391 Total long-lived assets $ 154,039 $ 145,348 Intangible assets: United States and Canada $ 556,951 $ 417,430 Europe 16,637 21,386 Asia 5,841 7,516 Total intangible assets $ 579,429 $ 446,332

Note 13 - Quarterly Financial_2

Note 13 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2019
Notes Tables
Quarterly Financial Information [Table Text Block]	(in thousands, except per share data) 2019 First Quarter Second Quarter Third Quarter Fourth Quarter Year Net sales $ 162,970 $ 174,510 $ 184,861 $ 191,664 $ 714,006 Cost of sales $ 55,367 $ 61,492 $ 60,251 $ 63,405 $ 240,515 Net earnings $ 17,403 $ 17,556 $ 44,654 $ 16,459 $ 96,072 Earnings per common share: Basic $ 0.46 $ 0.46 $ 1.18 $ 0.43 $ 2.54 Diluted $ 0.45 $ 0.45 $ 1.15 $ 0.42 $ 2.47 Weighted average common shares outstanding: Basic 37,697 37,766 37,772 37,881 37,781 Diluted 38,813 38,748 38,861 39,135 38,892 (in thousands, except per share data) 2018 First Quarter Second Quarter Third Quarter Fourth Quarter Year Net sales $ 144,613 $ 154,153 $ 163,973 $ 180,254 $ 642,993 Cost of sales $ 46,745 $ 52,319 $ 53,712 $ 58,074 $ 210,850 Net earnings (1) $ 15,863 $ 48,847 $ 19,738 $ 41,701 $ 126,150 Earnings per common share: Basic $ 0.42 $ 1.30 $ 0.53 $ 1.09 $ 3.36 Diluted $ 0.42 $ 1.29 $ 0.52 $ 1.07 $ 3.31 Weighted average common shares outstanding: Basic 37,376 37,449 37,503 37,585 37,476 Diluted 37,705 37,926 38,142 38,347 38,055

Note 1 - Description of Busin_3

Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jul. 01, 2019USD ($)	Jul. 01, 2018USD ($)
Advertising Expense			$ 4,100	$ 3,800	$ 4,500
Available-for-Sale Securities, Debt Maturities, Date Range Low			90 days
Available-for-sale Securities, Debt Maturities, Date Range High			6 years
Impairment of Long-Lived Assets Held-for-use			$ 0	0	$ 0
Number of Reporting Units			1
Goodwill, Impairment Loss			$ 0
Available-for-sale Securities, Total			38,200	54,300			$ 54,300
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax, Total							35,400
Deferred Tax Liabilities, Other Comprehensive Income			4,542	8,384			8,300
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total			(83,521)	(44,814)
Retained Earnings (Accumulated Deficit), Ending Balance			$ 931,934	$ 876,931
Accounting Standards Update 2016-01 [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total							(27,100)
Retained Earnings (Accumulated Deficit), Ending Balance							27,100
Accounting Standards Update 2016-01 [Member] | Other Nonoperating Income (Expense) [Member]
Equity Securities, FV-NI, Gain (Loss), Total	$ 12,300	$ 2,900
Accounting Standards Update 2018-02 [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total							2,400
Retained Earnings (Accumulated Deficit), Ending Balance							$ (2,400)
Accounting Standards Update 2016-02 [Member] | Subsequent Event [Member]
Operating Lease, Right-of-Use Asset						$ 82,000
Operating Lease, Liability, Total						$ 82,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life			1 year
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life			20 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years
Building, Building Improvements and Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life			5 years
Building, Building Improvements and Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			40 years

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Cumulative Effect Adjustments to Retained Earnings (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Jun. 30, 2018
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards		$ 594
Retained Earnings [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	$ 24,780	$ 25,276
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	98
Accounting Standards Update 2016-01 [Member] | Retained Earnings [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	27,053
Accounting Standards Update 2018-02 [Member] | Retained Earnings [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	$ (2,371)

Note 2 - Revenue Recognition (D

Note 2 - Revenue Recognition (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Contract with Customer, Liability, Total	$ 10.4	$ 9.3
Contract with Customer, Liability, Revenue Recognized	$ 7

Note 2 - Revenue Recognition -

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Revenues, net	$ 714,006	$ 642,993	$ 563,003
UNITED STATES
Revenues, net	391,191	346,293	313,195
EMEA, excluding U.K. [Member]
Revenues, net	155,821	148,599	125,126
UNITED KINGDOM
Revenues, net	34,975	33,704	28,401
APAC, excluding Greater China [Member]
Revenues, net	52,913	48,392	41,463
CHINA
Revenues, net	57,799	47,950	39,078
Rest of World [Member]
Revenues, net	21,307	18,055	15,740
Consumables [Member]
Revenues, net	588,979	534,738	476,541
Instruments [Member]
Revenues, net	67,538	61,784	47,751
Service [Member]
Revenues, net	38,050	34,137	23,652
Product and Services [Member]
Revenues, net	694,567	630,659	547,944
Royalty [Member]
Revenues, net	$ 19,439	$ 12,334	$ 15,059

Note 3 - Supplemental Balance_3

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jul. 01, 2018
Available-for-sale Securities, Total	$ 38,200	$ 54,300		$ 54,300
Amortization of Intangible Assets, Total	58,715	47,076
Other Assets, Noncurrent, Total	5,668	5,266
Developed Technology Rights [Member] | Cost of Sales [Member]
Amortization of Intangible Assets, Total	33,300	25,300	$ 23,100
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]
Amortization of Intangible Assets, Total	25,400	21,600	$ 21,300
Other Noncurrent Assets [Member]
Inventory, Finished Goods, Net of Reserves, Non-current	3,239
ChemoCentryx, Inc (CCXI) [Member]
Available-for-sale Securities, Gross Realized Gain (Loss), Total	(16,100)
Available-for-sale Equity Securities, Amortized Cost Basis, Total	$ 18,800	$ 18,800
ChemoCentryx, Inc (CCXI) [Member]
Share Price	$ 9.30	$ 13.17

Note 3 - Supplemental Balance_4

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) - USD ($) $ in Thousands		Jun. 30, 2019	Jun. 30, 2018
Raw materials		$ 40,913	$ 30,956
Finished goods	[1]	53,376	54,692
Inventories, net		$ 94,289	$ 85,648
[1]	Finished goods inventory of $3,239 is included within other long-term assets in the June 30, 2019 Balance Sheet as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Note 3 - Supplemental Balance_5

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Property and equipment, cost	$ 306,317	$ 284,800
Accumulated depreciation and amortization	(152,278)	(139,452)
Property and equipment, net	154,039	145,348
Land [Member]
Property and equipment, cost	7,065	7,065
Building and Building Improvements [Member]
Property and equipment, cost	175,019	170,110
Machinery and Equipment [Member]
Property and equipment, cost	$ 124,233	$ 107,625

Note 3 - Supplemental Balance_6

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Intangible assets	$ 799,428	$ 608,540
Accumulated amortization	(219,999)	(162,208)
Intangibles assets, net	$ 579,429	446,332	$ 452,042
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	1 year
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	20 years
Developed Technology Rights [Member]
Intangible assets	$ 435,679	305,303
Developed Technology Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	9 years
Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	15 years
Trade Names [Member]
Intangible assets	$ 147,296	89,608
Trade Names [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Trade Names [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	20 years
Customer Relationships [Member]
Intangible assets	$ 214,320	212,228
Customer Relationships [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	7 years
Customer Relationships [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	16 years
Patents [Member]
Finite-Lived Intangible Asset, Useful Life	10 years
Intangible assets	$ 2,133	$ 1,401

Note 3 - Supplemental Balance_7

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Beginning balance	$ 446,332	$ 452,042
Acquisitions (Note 4)	191,956	40,673
Other additions	633	908
Amortization expense	(58,715)	(47,076)
Currency translation	(777)	(215)
Ending balance	$ 579,429	$ 446,332

Note 3 - Supplemental Balance_8

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Jun. 30, 2019USD ($)
2020	$ 59,905
2021	59,557
2022	57,905
2023	56,031
2024	53,464
Thereafter	292,567
Total	$ 579,429

Note 3 - Supplemental Balance_9

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Balance	$ 597,890	$ 579,026
Acquisitions (Note 4)	136,301	19,096
Currency translation	(1,524)	(232)
Balance	732,667	597,890
Protein Sciences [Member]
Balance	347,918	331,789
Acquisitions (Note 4)	30,939	16,186
Currency translation	(1,450)	(56)
Balance	377,407	347,918
Diagnostics and Genomics [Member]
Balance	249,972	247,237
Acquisitions (Note 4)	105,362	2,910
Currency translation	(74)	(176)
Balance	$ 355,260	$ 249,972

Note 3 - Supplemental Balanc_10

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Investments		$ 2,606
Other	5,668	2,660
Other long-term assets	$ 5,668	$ 5,266

Note 3 - Supplemental Balanc_11

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income taxes paid		$ 36,814	$ 35,076	$ 42,900
Interest paid		21,497	9,844	7,452
Acquisition-related liabilities	[1]	$ 12,600	$ 1,396	$ 32,856
[1]	Consists of holdback payments due at future dates and liabilities for contingent consideration. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.

Note 4 - Acquisitions (Details

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 04, 2019	Aug. 01, 2018	Jul. 02, 2018	Feb. 01, 2018	Jan. 02, 2018	Sep. 05, 2017	Aug. 01, 2016	Jul. 01, 2016	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Payments to Acquire Businesses, Net of Cash Acquired, Total												$ 289,492			$ 67,851	$ 253,785
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability															(26,600)	$ (11,800)
Business Combination, Contingent Consideration, Liability, Total	$ 12,600									$ 12,600	$ 12,600	12,600	$ 12,600	$ 12,600
QT Holdings Corporation [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 20,404									20,462
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	51,000			51,000						51,000	51,000	51,000	51,000	51,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount				0
Goodwill, Purchase Accounting Adjustments													4,691	4,700
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	12,256			20,000						12,256	12,256	12,256	12,256	12,256
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles													(7,744)
Business Combination, Consideration Transferred, Total				25,604									25,762
Business Combination, Consideration Transferred, Liabilities Incurred				$ 5,200									5,300
QT Holdings Corporation [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life				14 years
Exosome Diagnostics, Inc [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	251,623		$ 251,825								251,600
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	325,000		325,000							325,000	325,000	$ 325,000	325,000	325,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount			0
Goodwill, Purchase Accounting Adjustments										8,770
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability										2,000
Business Combination, Consideration Transferred, Total			253,625							255,423
Business Combination, Consideration Transferred, Liabilities Incurred			1,800							3,800
Exosome Diagnostics, Inc [Member] | Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			250,000
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			45,000
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			30,000
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life												15 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			180,000
Exosome Diagnostics, Inc [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life												15 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	58,000									58,000	58,000	$ 58,000	58,000	58,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles										58,000
Exosome Diagnostics, Inc [Member] | Developed Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	105,000									105,000	105,000	$ 105,000	105,000	105,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles										(75,000)
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life												14 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	2,300									2,300	2,300	$ 2,300	2,300	2,300
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles										2,300
B-MoGen [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 17,448
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 38,000	38,000								$ 38,000	$ 38,000	38,000	$ 38,000	$ 38,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount		0
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value		1,400
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain		3,700
Business Combination, Consideration Transferred, Liabilities Incurred		$ 5,500
B-MoGen [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life		14 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 14,000
B-MoGen [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 400
Trevigen Inc. [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total							$ 10,600					10,644
Business Acquisition, Goodwill, Expected Tax Deductible Amount							$ 0
Business Combination, Consideration Transferred, Total												10,644
Business Combination, Consideration Transferred, Liabilities Incurred
Atlanta Biologicals [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total												51,274
Business Acquisition, Goodwill, Expected Tax Deductible Amount						$ 0
Business Combination, Consideration Transferred, Total						$ 51,300						51,274
Business Combination, Consideration Transferred, Liabilities Incurred
Atlanta Biologicals [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life						13 years
Atlanta Biologicals [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life						15 years
Atlanta Biologicals [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life						12 years
Eurocell Diagnostics, SAS [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total												5,933
Business Acquisition, Goodwill, Expected Tax Deductible Amount					$ 0
Business Combination, Consideration Transferred, Total					7,300							7,329
Payments to Acquire Businesses, Gross					6,000
Business Combination, Consideration Transferred, Liabilities Incurred					$ 1,300							1,396
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life					7 years
Advanced Cell Diagnostics (ACD) [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total								$ 247,000				247,038
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High								75,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount								0
Business Combination, Consideration Transferred, Total												287,638
Payments to Acquire Businesses, Gross								258,000
Business Combination, Consideration Transferred, Liabilities Incurred								$ 11,000				3,600
Business Combination, Consideration Transferred, Employee Vesting Period								1 year 180 days
Advanced Cell Diagnostics (ACD) [Member] | Pre-acquisition Services [Member]
Business Combination, Consideration Transferred, Liabilities Incurred								$ 3,600
Advanced Cell Diagnostics (ACD) [Member] | Future Services [Member]
Business Combination, Consideration Transferred, Liabilities Incurred								7,400
Advanced Cell Diagnostics (ACD) [Member] | The 2016 Revenue Equal or Exceed $30 Milliom [Member]
Business Combination, Contingent Consideration, Liability, Total								25,000
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue								30,000
Advanced Cell Diagnostics (ACD) [Member] | The 2017 Revenues Equal or Exceed $45 Million [Member]
Business Combination, Contingent Consideration, Liability, Total								50,000
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue								$ 45,000
Space [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total									$ 6,700			6,747
Business Acquisition, Goodwill, Expected Tax Deductible Amount									0
Business Combination, Consideration Transferred, Total												9,003
Payments to Acquire Businesses, Gross									9,000
Business Combination, Consideration Transferred, Liabilities Incurred									$ 2,300			$ 2,256

Note 4 - Acquisitions - Prelimi

Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 04, 2019	Aug. 01, 2018	Jul. 02, 2018	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Goodwill	$ 732,667				$ 732,667	$ 732,667	$ 732,667	$ 732,667	$ 732,667	$ 597,890	$ 579,026
Payments to Acquire Businesses, Net of Cash Acquired, Total							289,492			$ 67,851	$ 253,785
QT Holdings Corporation [Member]
Current assets, net of cash	36			$ 36	36	36	36	36	36
Equipment and other long-term assets	228			284	228	228	228	228	228
Equipment and other long-term assets								(56)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	12,256			20,000	12,256	12,256	12,256	12,256	12,256
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles								(7,744)
Goodwill	14,481			9,790	14,481	14,481	14,481	14,481	14,481
Goodwill, Purchase Accounting Adjustments								4,691	4,700
Total assets acquired	27,001			30,110	27,001	27,001	27,001	27,001	27,001
Total assets acquired, adjustments								(3,109)
Liabilities	296			765	296	296	296	296	296
Liabilities, adjustments								(469)
Deferred income taxes, net	943			3,741	943	943	943	943	943
Deferred income taxes, net, adjustments								(2,798)
Net assets acquired	25,762			25,604	25,762	25,762	25,762	25,762	25,762
Net assets acquired, adjustments								158
Payments to Acquire Businesses, Net of Cash Acquired, Total				20,404				20,462
Cash paid, net of cash acquired, adjustments								58
Business Combination, Consideration Transferred, Liabilities Incurred				5,200				5,300
Fair value of contingent consideration, adjustments								100
Business Combination, Consideration Transferred, Total				$ 25,604				25,762
Exosome Diagnostics, Inc [Member]
Current assets, net of cash	2,611		$ 5,118		2,611	2,611	2,611	2,611	2,611
Equipment and other long-term assets	2,212		2,212		2,212	2,212	2,212	2,212	2,212
Goodwill	105,362		96,592		105,362	105,362	105,362	105,362	105,362
Goodwill, Purchase Accounting Adjustments					8,770
Total assets acquired	275,485		283,922		275,485	275,485	275,485	275,485	275,485
Liabilities	3,716		2,624		3,716	3,716	3,716	3,716	3,716
Liabilities, adjustments					1,092
Deferred income taxes, net	16,346		27,673		16,346	16,346	16,346	16,346	16,346
Deferred income taxes, net, adjustments					(11,327)
Net assets acquired	255,423		253,625		255,423	255,423	255,423	255,423	255,423
Net assets acquired, adjustments					1,798
Payments to Acquire Businesses, Net of Cash Acquired, Total	251,623		251,825			251,600
Cash paid, net of cash acquired, adjustments					1,798
Business Combination, Consideration Transferred, Liabilities Incurred			1,800		3,800
Fair value of contingent consideration, adjustments					2,000
Business Combination, Consideration Transferred, Total			253,625		255,423
Current assets, net of cash, adjustment					(2,507)
Total assets acquired, adjustment					(8,437)
Cash paid, net of cash acquired, adjustment					(202)
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			180,000
Exosome Diagnostics, Inc [Member] | Developed Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	105,000				105,000	105,000	105,000	105,000	105,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles					(75,000)
Exosome Diagnostics, Inc [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	58,000				58,000	58,000	58,000	58,000	58,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles					58,000
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 2,300				2,300	$ 2,300	$ 2,300	$ 2,300	$ 2,300
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles					$ 2,300
B-MoGen [Member]
Current assets, net of cash		$ 504
Equipment and other long-term assets		269
Goodwill		16,457
Total assets acquired		31,630
Liabilities		211
Deferred income taxes, net		3,377
Net assets acquired		28,042
Payments to Acquire Businesses, Net of Cash Acquired, Total		17,448
Business Combination, Consideration Transferred, Liabilities Incurred		5,500
Fair value of historical investment in B-MoGen		5,094
Net assets acquired		28,042
B-MoGen [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		14,000
B-MoGen [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 400

Note 4 - Acquisitions - Pro For

Note 4 - Acquisitions - Pro Forma Financial Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Net sales	$ 564,220	$ 523,840
Net income	$ 99,380	$ 110,536

Note 4 - Acquisitions - Estimat

Note 4 - Acquisitions - Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Feb. 01, 2018	Jan. 02, 2018	Sep. 05, 2017	Aug. 01, 2016	Jul. 01, 2016	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill						$ 732,667	$ 597,890	$ 579,026
Payments to Acquire Businesses, Net of Cash Acquired, Total						289,492	67,851	$ 253,785
Contingent consideration payable						9,200
Trevigen Inc. [Member]
Current assets, net of cash						1,662
Equipment and other long-term assets						53
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill						5,991
Total assets acquired						13,226
Liabilities						387
Deferred income taxes, net						2,195
Net assets acquired						10,644
Payments to Acquire Businesses, Net of Cash Acquired, Total			$ 10,600			10,644
Business Combination, Consideration Transferred, Liabilities Incurred
Contingent consideration payable
Net assets acquired						10,644
Trevigen Inc. [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						5,100
Trevigen Inc. [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						160
Trevigen Inc. [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						260
Atlanta Biologicals [Member]
Current assets, net of cash						15,722
Equipment and other long-term assets						4,901
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill						10,195
Total assets acquired						59,718
Liabilities						90
Deferred income taxes, net						8,354
Net assets acquired						51,274
Payments to Acquire Businesses, Net of Cash Acquired, Total						51,274
Business Combination, Consideration Transferred, Liabilities Incurred
Contingent consideration payable
Net assets acquired		$ 51,300				51,274
Atlanta Biologicals [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						23,000
Atlanta Biologicals [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						2,300
Atlanta Biologicals [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						3,600
Eurocell Diagnostics, SAS [Member]
Current assets, net of cash						512
Equipment and other long-term assets						188
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill						2,910
Total assets acquired						9,882
Liabilities						483
Deferred income taxes, net						2,070
Net assets acquired						7,329
Payments to Acquire Businesses, Net of Cash Acquired, Total						5,933
Business Combination, Consideration Transferred, Liabilities Incurred	$ 1,300					1,396
Contingent consideration payable
Net assets acquired	$ 7,300					7,329
Eurocell Diagnostics, SAS [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets
Eurocell Diagnostics, SAS [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						6,272
Advanced Cell Diagnostics (ACD) [Member]
Current assets, net of cash						15,824
Equipment and other long-term assets						6,569
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill						143,967
Total assets acquired						344,560
Liabilities						4,179
Deferred income taxes, net						52,743
Net assets acquired						287,638
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 247,000		247,038
Business Combination, Consideration Transferred, Liabilities Incurred				$ 11,000		3,600
Contingent consideration payable						37,000
Net assets acquired						287,638
Advanced Cell Diagnostics (ACD) [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						150,000
Advanced Cell Diagnostics (ACD) [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						21,900
Advanced Cell Diagnostics (ACD) [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						6,300
Space [Member]
Current assets, net of cash						2,128
Equipment and other long-term assets						159
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill						3,517
Total assets acquired						12,573
Liabilities						1,445
Deferred income taxes, net						2,125
Net assets acquired						9,003
Payments to Acquire Businesses, Net of Cash Acquired, Total					$ 6,700	6,747
Business Combination, Consideration Transferred, Liabilities Incurred					$ 2,300	2,256
Contingent consideration payable
Net assets acquired						9,003
Space [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets
Space [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets
Space [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets						$ 6,769

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	11 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 04, 2019	Oct. 31, 2018	Aug. 01, 2018	Jul. 02, 2018
Business Combination, Liabilities Arising from Contingencies, Amount Recognized					$ 14,600
Payment for Contingent Consideration Liability			$ 88,500
Payment for Contingent Consideration Liability, Financing Activities			61,900	$ 20,316
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			(26,600)	$ (11,800)
Exosome Diagnostics, Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 325,000	325,000					$ 325,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized							$ 3,800
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	2,000
QT Holdings Corporation [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	51,000	51,000						$ 51,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized								$ 5,300
B-MoGen [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	38,000	38,000			38,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized					$ 5,500
Embedded Derivative Financial Instruments [Member]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax		0
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member]
Derivative, Notional Amount						$ 380,000
CCXI [Member]
Investments, Total	$ 18,800	$ 18,800	$ 18,800

Note 5 - Fair Value Measureme_4

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands		Jun. 30, 2019	Jun. 30, 2018
Total Assets		$ 65,147	$ 59,764
Business Combination, Contingent Consideration, Liability, Total		12,600
Derivative instruments - cash flow hedges		12,458
Total Liabilities		25,058
Fair Value, Inputs, Level 1 [Member]
Total Assets		65,147	59,764
Business Combination, Contingent Consideration, Liability, Total
Derivative instruments - cash flow hedges
Total Liabilities
Fair Value, Inputs, Level 2 [Member]
Total Assets
Business Combination, Contingent Consideration, Liability, Total
Derivative instruments - cash flow hedges		12,458
Total Liabilities		12,458
Fair Value, Inputs, Level 3 [Member]
Total Assets
Business Combination, Contingent Consideration, Liability, Total		12,600
Derivative instruments - cash flow hedges
Total Liabilities		12,600
Equity Securities [Member]
Investments, Fair Value Disclosure	[1]	38,219	54,286
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[1]	38,219	54,286
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[1]
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[1]
Certificates of Deposit [Member]
Investments, Fair Value Disclosure	[2]	26,928	5,478
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[2]	26,928	5,478
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[2]
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[2]
[1]	Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2019 and June 30, 2018 was $18.8 million.
[2]	Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year.

Note 5 - Fair Value Measureme_5

Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Fair value at the beginning of period		$ 68.4
Purchase price contingent consideration (Note 4)	14.6
Payments		(88.5)
Change in fair value of contingent consideration	(2)	20.1
Contingent consideration payable	$ 12.6

Note 6 - Debt and Other Finan_2

Note 6 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Thousands	Aug. 01, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Proceeds from Long-term Lines of Credit		$ 580,000	$ 55,000	$ 368,500
Credit Agreement [Member]
Long-term Debt, Total		505,200
Credit Agreement [Member] | Term Loan [Member]
Debt Instrument, Face Amount	$ 250,000
Proceeds from Issuance of Long-term Debt, Total	250,000
Revolving Credit Facility [Member] | Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity	600,000
Line of Credit Facility, Additional Borrowing Capacity	$ 200,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.20%
Line of Credit, Current		$ 12,500
Proceeds from Long-term Lines of Credit	$ 330,000

Note 7 - Commitments and Cont_3

Note 7 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Operating Leases, Rent Expense, Net, Total	$ 12.9	$ 10.8	$ 9.8

Note 7 - Commitments and Cont_4

Note 7 - Commitments and Contingencies - Aggregate Net Minimum Rental Commitments (Details) $ in Thousands	Jun. 30, 2019USD ($)
2020	$ 13,707
2021	13,469
2022	13,154
2023	12,716
2024	11,392
Thereafter	51,895
Total	$ 116,333

Note 8 - Supplemental Equity _3

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Common Stock, Dividends, Per Share, Declared		$ 1.28	$ 1.28	$ 1.28
Stock Repurchased During Period, Shares		95,000
Stock Repurchased During Period, Average Share Price		$ 162.15
Stockholders' Equity Attributable to Parent, Ending Balance		$ 1,165,589	$ 1,079,061	$ 949,627	$ 879,280
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent
Stockholders' Equity Attributable to Parent, Ending Balance		$ (9,537)
Forecast [Member]
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	$ (1,748)

Note 8 - Supplemental Equity _4

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2019		Jun. 30, 2018	Jun. 30, 2017	Jul. 01, 2018
Balance		$ 1,079,061		$ 949,627	$ 879,280
Cumulative effect adjustment for adoption				594
Balance		1,165,589		1,079,061	949,627
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]
Balance		24,682		18,989	(5,542)
Other comprehensive income (loss) before reclassifications			[1]	18,108	24,531
Amounts reclassified from accumulated other comprehensive loss to income				(12,415)
Balance				24,682	18,989
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2018-02 [Member]
Cumulative effect adjustment for adoption	[2]					$ 2,371
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2016-01 [Member]
Cumulative effect adjustment for adoption	[2]					(27,053)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance		(69,496)		(67,924)	(64,863)
Other comprehensive income (loss) before reclassifications		(4,487)	[1]	(1,572)	(3,061)
Amounts reclassified from accumulated other comprehensive loss to income
Balance		(73,983)		(69,496)	(67,924)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member]
Cumulative effect adjustment for adoption	[2]
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member]
Cumulative effect adjustment for adoption	[2]
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]
Balance
Other comprehensive income (loss) before reclassifications		(9,537)	[1]
Amounts reclassified from accumulated other comprehensive loss to income
Balance		(9,537)
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2018-02 [Member]
Cumulative effect adjustment for adoption	[2]
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2016-01 [Member]
Cumulative effect adjustment for adoption	[2]
AOCI Attributable to Parent [Member]
Balance		(44,814)		(48,935)	(70,405)
Other comprehensive income (loss) before reclassifications		(14,024)	[1]	16,536	21,470
Amounts reclassified from accumulated other comprehensive loss to income				(12,415)
Cumulative effect adjustment for adoption				(24,682)
Balance		$ (83,521)		$ (44,814)	$ (48,935)
AOCI Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member]
Cumulative effect adjustment for adoption	[2]					2,371
AOCI Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member]
Cumulative effect adjustment for adoption	[2]					$ (27,053)
[1]	The gain (loss) on the forward starting interest rate swap will be reclassified into earnings beginning October 31, 2019. Approximately ($1,748) of the ($9,537) will be reclassified into earnings in the 12 months subsequent to June 30, 2019.
[2]	See Note 1 for further information related to the adoption of ASU 2016-01 and 2018-02.

Note 9 - Earnings Per Share (De

Note 9 - Earnings Per Share (Details Textual) - shares shares in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1.3	0.9	2

Note 9 - Earnings Per Share - S

Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Net earnings	$ 16,459	$ 44,654	$ 17,556	$ 17,403	$ 41,701	$ 19,738	$ 48,847	$ 15,863	$ 96,072	$ 126,150	$ 76,086
Income allocated to participating securities									(105)	(108)	(65)
Income available to common shareholders									$ 95,967	$ 126,042	$ 76,021
Basic (in shares)	37,881	37,772	37,766	37,697	37,585	37,503	37,449	37,376	37,781	37,476	37,313
Basic (in dollars per share)	$ 0.43	$ 1.18	$ 0.46	$ 0.46	$ 1.09	$ 0.53	$ 1.30	$ 0.42	$ 2.54	$ 3.36	$ 2.04
Net income	$ 16,459	$ 44,654	$ 17,556	$ 17,403	$ 41,701	$ 19,738	$ 48,847	$ 15,863	$ 96,072	$ 126,150	$ 76,086
Income available to common shareholders									$ 95,967	$ 126,042	$ 76,021
Dilutive effect of stock options and restricted stock units (in shares)									1,111	579	187
Diluted (in shares)	39,135	38,861	38,748	38,813	38,347	38,142	37,926	37,705	38,892	38,055	37,500
Diluted (in dollars per share)	$ 0.42	$ 1.15	$ 0.45	$ 0.45	$ 1.07	$ 0.52	$ 1.29	$ 0.42	$ 2.47	$ 3.31	$ 2.03

Note 10 - Share-based Compens_3

Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	3,656,000	3,452,000	2,821,000	1,819,000
Share-based Payment Arrangement, Accelerated Cost		$ 8.3
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 34.66	$ 22.07	$ 18.21
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 159	$ 10.6	$ 2.3
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	31.7	8.8	5
Share-based Payment Arrangement, Expense, Tax Benefit		0.4	0.5
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 26.6
Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate	3.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years
US Profit Sharing and Savings Plan [Member]
Defined Contribution Plan, Cost	$ 2.8	2.5	2.2
GB Profit Sharing and Savings Plan [Member]
Defined Contribution Plan, Cost	1.4	1.4	0.8
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense	32.3	28.2	14.6
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	2.3	1.7	1.4
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 3.1	$ 1.6	0.9
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Equity Incentive Plan 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	7,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	3,600,000
Equity Incentive Plan 2010 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Nonqualified Stock Options Plan 1998 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	20,000
Employee Stock Purchase Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000
Share-based Payment Arrangement, Expense	$ 0.5	$ 0.3	0.2
Performance Incentive Programs [Member] | Executive Officer [Member]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	$ 9.3	$ 7.2	$ 4.7
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	618,898	553,750	896,778
Performance Incentive Programs [Member] | Restricted Stock [Member] | Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	11,279	14,194	16,653
Performance Incentive Programs [Member] | Restricted Stock Units (RSUs) [Member] | Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	25,903	35,174		39,931

Note 10 - Share-based Compens_4

Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Dividend yield	0.74%	1.10%	1.20%
Expected lives (years) (Year)	4 years 36 days	4 years 255 days	4 years 255 days
Minimum [Member]
Expected volatility	20.00%	20.00%	21.00%
Risk-free interest rates	2.50%	1.70%	1.00%
Maximum [Member]
Expected volatility	23.00%	21.00%	24.00%
Risk-free interest rates	3.00%	2.80%	1.90%

Note 10 - Share-based Compens_5

Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Outstanding, shares (in shares)	3,452	2,821	1,819
Outstanding, weighted average exercise price (in dollars per share)	$ 105.17	$ 98.42	$ 91.91
Granted, shares (in shares)	917	1,087	1,135
Granted, weighted average exercise price (in dollars per share)	$ 173.89	$ 120.67	$ 107.42
Forfeited, shares (in shares)	(330)	(252)	(70)
Forfeited, weighted average exercise price (in dollars per share)	$ 129.93	$ 86.62	$ 99.11
Exercised, shares (in shares)	(383)	(204)	(63)
Exercised, weighted average exercise price (in dollars per share)	$ 95.29	$ 111.51	$ 71.81
Outstanding, shares (in shares)	3,656	3,452	2,821
Outstanding, weighted average exercise price (in dollars per share)	$ 121.16	$ 105.17	$ 98.42
Outstanding, aggregate intrinsic value	$ 319.3
Outstanding, weighted average contractual life (Year)	4 years 164 days
Exercisable, shares (in shares)	1,467	1,151	843
Exercisable, weighted average exercise price (in dollars per share)	$ 98.70	$ 90.75	$ 82.93
Exercisable, aggregate intrinsic value	$ 161
Exercisable, weighted average contractual life (Year)	3 years 120 days

Note 10 - Share-based Compens_6

Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Restricted Stock [Member]
Balance, shares (in shares)	35	32	23
Balance, weighted average exercise price (in dollars per share)	$ 117.39	$ 105.80	$ 98.03
Granted, shares (in shares)	15	20	24
Granted, weighted average exercise price (in dollars per share)	$ 177.93	$ 125.05	$ 104.94
Vested, shares (in shares)	(20)	(17)	(15)
Vested, weighted average exercise price (in dollars per share)	$ 116.76	$ 104.66	$ 92.62
Forfeited, shares (in shares)
Forfeited, weighted average exercise price (in dollars per share)
Balance, shares (in shares)	30	35	32
Balance, weighted average exercise price (in dollars per share)	$ 117.39	$ 117.39	$ 105.80
Balance, weighted average contractual life (Year)	5 years 321 days
Forfeited, shares (in shares)
Forfeited, shares (in shares)
Restricted Stock Units (RSUs) [Member]
Balance, shares (in shares)	148	111	59
Balance, weighted average exercise price (in dollars per share)	$ 117.95	$ 106.39	$ 100.40
Granted, shares (in shares)	56	71	65
Granted, weighted average exercise price (in dollars per share)	$ 170.96	$ 129.99	$ 109.36
Vested, shares (in shares)	(28)	(16)	(9)
Vested, weighted average exercise price (in dollars per share)	$ 110.86	$ 95.46	$ 92.94
Forfeited, shares (in shares)	36	18	4
Forfeited, weighted average exercise price (in dollars per share)	$ 143.72	$ 115.01	$ 98.04
Balance, shares (in shares)	139	148	111
Balance, weighted average exercise price (in dollars per share)	$ 134.17	$ 117.95	$ 106.39
Balance, weighted average contractual life (Year)	5 years 62 days
Forfeited, shares (in shares)	(36)	(18)	(4)
Forfeited, shares (in shares)	(36)	(18)	(4)

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Effective Income Tax Rate Reconciliation, Percent, Total	14.20%	(0.20%)	32.00%
Income Tax Expense (Benefit), Discrete Tax Items	$ 12,700	$ 34,400
Excess Tax Benefit from Share-based Compensation, Operating Activities	7,200
Income Tax Expense (Benefit), Discrete Tax Items, Acquisitions	(3,200)
Income Tax Expense (Benefit) Discrete Tax Items State Apportionments	2,000
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount		33,000
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		36,500
Income Tax Expense (Benefit), Federal Translation Tax		3,300
Income Tax Expense (Benefit), Stock Options Exercises		2,200
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Revaluation of Contingent Consideration		4,200
Deferred Tax Assets, Valuation Allowance, Total	6,974	2,978
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	4,000
Deferred Tax Assets, Net of Valuation Allowance, Total	65,597	$ 40,345
Undistributed Earnings of Foreign Subsidiaries	160,000
Operating Loss Carryforwards [Member]
Deferred Tax Assets, Net of Valuation Allowance, Total	28,200
Tax Credit Carryforwards [Member]
Deferred Tax Assets, Net of Valuation Allowance, Total	7,700
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	98,200
Tax Credit Carryforward, Amount	5,200
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	137,400
Tax Credit Carryforward, Amount	4,400
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 13,600

Note 11 - Income Taxes - Compon

Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Domestic	$ 64,081	$ 81,557	$ 81,721
Foreign	47,934	44,395	30,240
Income before income taxes	112,015	125,952	111,961
Federal	16,090	28,416	28,462
State	544	5,315	4,051
Foreign	13,329	11,983	8,212
Total current tax provision	29,963	45,714	40,725
Federal	(6,903)	(40,378)	(901)
State	(3,977)	(1,381)	(968)
Foreign	(3,142)	(4,154)	(2,981)
Total deferred tax provision	(14,021)	(45,912)	(4,850)
Total income tax provision	$ 15,942	$ (198)	$ 35,875

Note 11 - Income Taxes - Reconc

Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income tax expense at federal statutory rate	21.00%	28.10%	35.00%
State income taxes, net of federal benefit	0.80%	2.50%	1.90%
Qualified production activity deduction		(2.40%)	(3.40%)
Research and development tax credit	(1.60%)	(1.40%)	(1.40%)
Contingent consideration adjustment	(0.40%)	3.30%	4.10%
Foreign tax rate differences	0.20%	(3.50%)	(4.60%)
Option exercises	(5.80%)	(1.80%)
Domestic tax legislation changes	1.70%	(26.20%)
State apportionment changes	(2.30%)
Other, net	0.60%	1.20%	0.40%
Effective tax rate	14.20%	(0.20%)	32.00%

Note 11 - Income Taxes - Tempor

Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jul. 01, 2018	Jun. 30, 2018
Inventory	$ 7,743		$ 5,873
Net operating loss carryovers	33,294		15,938
Tax credit carryovers	9,640		7,029
Excess tax basis in equity investments	3,433		2,813
Deferred compensation	10,333		7,806
Derivative - cash flow hedge	2,921
Other	5,207		3,864
Valuation allowance	(6,974)		(2,978)
Deferred tax assets	65,597		40,345
Net unrealized gain on available-for-sale investments	(4,542)	$ (8,300)	(8,384)
Intangible asset amortization	(141,998)		(111,247)
Depreciation	(8,371)		(6,349)
Other	440		658
Deferred tax liabilities	(155,351)		(126,638)
Net deferred tax liabilities	$ (89,754)		$ (86,293)

Note 11 - Income Taxes - Reco_2

Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Balance	$ 1,947	$ 1,747	$ 1,480
Additions due to acquisitions	900		628
Additions for tax positions of current year	2,185	35	13
Closure of tax years			(374)
Tax reform		165
Ending balances	$ 5,032	$ 1,947	$ 1,747

Note 12 - Segment Information_2

Note 12 - Segment Information (Details Textual)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Number of Reportable Segments	2
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Protein Sciences [Member]
Number of Major Customers	0	0	0
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Diagnostics and Genomics [Member]
Number of Major Customers	0	0	0

Note 12 - Segment Information -

Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Revenues, net	$ 714,006,000	$ 642,993,000	$ 563,003,000
Operating income	146,719,000	136,178,000	120,584,000
Costs recognized upon sale of acquired inventory	(3,739,000)	(2,455,000)	(3,037,000)
Amortization of acquired intangible assets	(58,550,000)	(46,983,000)	(44,393,000)
Restructuring costs		(376,000)
Corporate general, selling and administrative expenses	(264,359,000)	(240,636,000)	(200,443,000)
Net sales	714,006,000	642,993,000	563,003,000
United States and Canada	154,039,000	145,348,000
Intangible assets, net	579,429,000	446,332,000	452,042,000
United States and Canada [Member]
United States and Canada	138,016,000	129,360,000
Intangible assets, net	556,951,000	417,430,000
Europe [Member]
United States and Canada	14,439,000	14,597,000
Intangible assets, net	16,637,000	21,386,000
Asia [Member]
United States and Canada	1,584	1,391
Intangible assets, net	5,841	7,516
Consumables [Member]
Revenues, net	588,979,000	534,738,000	476,541,000
Net sales	588,979,000	534,738,000	476,541,000
Protein Sciences [Member] | Consumables [Member]
Revenues, net	430,655,000	384,350,000	341,611,000
Net sales	430,655,000	384,350,000	341,611,000
Diagnostics and Genomics [Member] | Consumables [Member]
Revenues, net	158,324,000	150,388,000	134,930,000
Net sales	158,324,000	150,388,000	134,930,000
Operating Segments [Member]
Operating income	250,998,000	245,376,000	213,386,000
Operating Segments [Member] | Protein Sciences [Member]
Revenues, net	543,159,000	482,378,000	419,365,000
Operating income	240,919,000	209,880,000	184,095,000
Net sales	543,159,000	482,378,000	419,365,000
Operating Segments [Member] | Diagnostics and Genomics [Member]
Revenues, net	171,674,000	161,151,000	143,742,000
Operating income	10,079,000	35,496,000	29,291,000
Net sales	171,674,000	161,151,000	143,742,000
Intersegment Eliminations [Member]
Revenues, net	(827,000)	(536,000)	(104,000)
Net sales	(827,000)	(536,000)	(104,000)
Segment Reconciling Items [Member]
Acquisition related expenses	(2,282,000)	(24,429,000)	(25,789,000)
Stock-based compensation	(33,057,000)	(28,240,000)	(14,631,000)
Corporate, Non-Segment [Member]
Corporate general, selling and administrative expenses	$ (6,651,000)	$ (6,715,000)	$ (4,952,000)

Note 13 - Quarterly Financial_3

Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Net sales	$ 191,664	$ 184,861	$ 174,510	$ 162,970	$ 180,254	$ 163,973	$ 154,153	$ 144,613	$ 714,006	$ 642,993
Cost of sales	63,405	60,251	61,492	55,367	58,074	53,712	52,319	46,745	240,515	210,850	$ 188,462
Net earnings	$ 16,459	$ 44,654	$ 17,556	$ 17,403	$ 41,701	$ 19,738	$ 48,847	$ 15,863	$ 96,072	$ 126,150	$ 76,086
Basic (in dollars per share)	$ 0.43	$ 1.18	$ 0.46	$ 0.46	$ 1.09	$ 0.53	$ 1.30	$ 0.42	$ 2.54	$ 3.36	$ 2.04
Diluted (in dollars per share)	$ 0.42	$ 1.15	$ 0.45	$ 0.45	$ 1.07	$ 0.52	$ 1.29	$ 0.42	$ 2.47	$ 3.31	$ 2.03
Basic (in shares)	37,881	37,772	37,766	37,697	37,585	37,503	37,449	37,376	37,781	37,476	37,313
Diluted (in shares)	39,135	38,861	38,748	38,813	38,347	38,142	37,926	37,705	38,892	38,055	37,500